enVVeno Medical Corporation (NVNO) Income Statement
NVNO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsNVNO revenue and net income
NVNO profit margins
NVNO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NVNO quarterly EPS vs estimates
enVVeno Medical beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: October 30, 2026.
NVNO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $31,243 | $186,552 | $422,111 | $785,912 |
| Cost of revenue | $489,000 | $528,000 | $546,000 | $525,000 | $452,909 | $383,972 | $0 | $0 | $558,872 | $961,468 |
| Gross profit | −$489,000 | −$528,000 | −$546,000 | −$525,000 | −$452,909 | −$383,972 | $31,243 | $186,552 | −$136,761 | −$175,556 |
| Research & development | $10.0M | $12.2M | $13.6M | $9.9M | $5.7M | $4.3M | $2.2M | $1.2M | $649,736 | — |
| Sales, general & admin | $10.9M | $11.6M | $12.0M | $15.0M | $11.2M | $4.9M | $4.9M | $6.5M | $5.5M | — |
| Total operating expenses | $20.9M | $23.3M | $24.7M | $24.4M | $16.4M | $8.8M | $7.7M | $8.0M | $6.0M | $4.5M |
| Operating income | −$20.9M | −$23.8M | −$25.2M | −$24.9M | −$16.9M | −$9.1M | −$7.7M | −$7.9M | −$6.1M | −$4.7M |
| Interest income | $692,000 | $389,000 | $172,000 | $161,000 | $19,000 | — | $49,915 | — | — | — |
| Interest expense | — | — | — | $263,000 | $18,709 | $3,739 | $933 | $6.9M | $1.9M | $57,890 |
| Income before taxes | −$19.5M | −$21.8M | −$23.5M | −$24.7M | −$16.5M | −$9.1M | −$7.6M | −$13.0M | −$7.8M | −$5.6M |
| Income taxes | — | — | — | −$365,000 | −$331,409 | −$215,546 | $863,542 | $1.7M | $209,506 | −$2.1M |
| Net income | −$19.5M | −$21.8M | −$23.5M | −$24.7M | −$16.5M | −$9.1M | −$7.6M | −$13.0M | −$7.8M | −$5.9M |
| EBITDA | −$19.0M | −$21.3M | −$23.0M | −$24.1M | −$16.1M | −$8.8M | −$7.2M | −$6.0M | −$5.7M | −$5.4M |
| EPS (diluted) | −$17.91 | −$44.45 | −$56.36 | −$41.97 | −$52.28 | −$327.39 | −$201.51 | −$1.58 | −$0.31 | — |
| Gross margin | — | — | — | — | — | — | 100.0% | 100.0% | −32.4% | −22.3% |
| Operating margin | — | — | — | — | — | — | −24,566.5% | −4,210.5% | −1,445.9% | −592.8% |
| Net margin | — | — | — | — | — | — | −24,406.7% | −6,991.5% | −1,845.8% | −749.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $812,000 | $0 | $0 | $0 | $824,000 | $0 |
| Cost of revenue | — | $124,000 | $117,000 | $120,000 | $130,000 | $122,000 | $122,000 | $129,000 | $136,000 | $141,000 | $134,000 | $138,000 |
| Gross profit | — | −$124,000 | −$117,000 | −$120,000 | −$130,000 | −$122,000 | −$122,000 | −$129,000 | −$136,000 | −$141,000 | −$134,000 | −$138,000 |
| Research & development | $2.1M | $2.1M | $1.9M | $2.6M | $2.9M | $2.6M | $3.5M | $2.9M | $2.8M | $3.1M | $3.0M | $2.8M |
| Sales, general & admin | $1.7M | $2.0M | $2.1M | $2.3M | $4.2M | $2.4M | $3.2M | $3.3M | $2.6M | $2.5M | $3.3M | $2.6M |
| Total operating expenses | $3.8M | $4.1M | $3.9M | $4.8M | $6.9M | $4.8M | $6.6M | $6.0M | $5.3M | $5.4M | $6.1M | $5.2M |
| Operating income | −$3.8M | −$4.1M | −$4.0M | −$4.9M | −$7.0M | −$5.0M | −$6.7M | −$6.2M | −$5.5M | −$5.5M | −$6.3M | −$5.3M |
| Interest income | $9,000 | $22,000 | $103,000 | $175,000 | $195,000 | $219,000 | $163,000 | $94,000 | $73,000 | $59,000 | $52,000 | $44,000 |
| Interest expense | — | — | — | — | — | — | $389,000 | — | — | — | $405,000 | — |
| Income before taxes | −$3.6M | −$3.8M | −$3.7M | −$4.5M | −$6.7M | −$4.5M | −$6.2M | −$5.6M | −$5.0M | −$5.0M | −$5.6M | −$5.0M |
| Income taxes | — | — | — | — | — | −$4.5M | −$97,724 | −$129,000 | — | $97,724 | $1.5M | −$348,000 |
| Net income | −$3.6M | −$3.8M | −$3.7M | −$4.5M | −$6.7M | −$4.5M | −$6.2M | −$5.6M | −$5.0M | −$5.0M | −$5.6M | −$5.0M |
| EBITDA | −$3.6M | −$3.9M | −$3.6M | −$4.4M | −$6.6M | −$4.4M | −$6.1M | −$5.5M | −$4.8M | −$4.9M | −$5.5M | −$4.9M |
| EPS (diluted) | −$5.37 | −$5.89 | −$5.91 | −$0.23 | −$11.55 | −$0.22 | −$10.50 | −$12.25 | −$10.85 | −$10.85 | −$0.36 | −$15.75 |
| Gross margin | — | — | — | — | — | — | −15.0% | — | — | — | −16.3% | — |
| Operating margin | — | — | — | — | — | — | −825.0% | — | — | — | −761.9% | — |
| Net margin | — | — | — | — | — | — | −767.1% | — | — | — | −685.6% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NVNO's financial statements (latest annual report filed March 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NVNO financial results
enVVeno Medical reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $19.5 million. Diluted earnings per share came to −$17.91.
See the NVNO stock overview for the latest quote and news, or the NVNO chart for price history and technical indicators.
NVNO income statement FAQ
Does enVVeno Medical have revenue?
enVVeno Medical reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is enVVeno Medical profitable?
No. enVVeno Medical reported a net loss of $19.5 million in fiscal 2025.
How much does enVVeno Medical spend on research and development?
enVVeno Medical spent $10.0 million on research and development in fiscal 2025.
What are enVVeno Medical's earnings per share?
enVVeno Medical earned $-17.91 per diluted share in fiscal 2025, compared with $-44.45 a year earlier.
When will enVVeno Medical report its next earnings?
enVVeno Medical is expected to report results for the quarter ending September 30, 2026 on October 30, 2026.
When does enVVeno Medical's fiscal year end?
enVVeno Medical's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 26, 2026.